Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant has a diagnosis of plaque psoriasis for at least 6 months before the first administration of investigational medicinal product (IMP) as determined by the investigator.~* Participant has inadequately controlled plaque psoriasis currently treated with ustekinumab, and fulfils ALL of the following criteria:~  1. Ustekinumab administered at least 3 times at or higher than the approved dose or frequency before randomisation.~ 2. IGA ≥2 at screening and baseline.~ 3. Absolute PASI \>3 at screening and baseline.~* Participant has no evidence of active tuberculosis according to local standard of care for patients requiring initiation of a biologic treatment. Participants with adequately treated latent tuberculosis, according to local guidelines, are eligible.~Key Exclusion Criteria:~* Participant was diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions (e.g. eczema) that would interfere with evaluations of the effect of IMP on plaque psoriasis.~* Participant has clinically important active infections or infestations, chronic, recurrent, or latent infections or infestations, or is immunocompromised (e.g. human immunodeficiency virus).~* Participant has any systemic disease (e.g. renal failure, heart failure, hypertension, liver disease, diabetes, anaemia) considered by the investigator to be clinically significant and uncontrolled.~* Participant has a known history of Crohn's disease.~* Participant has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.~* Participant has a history of malignancy within 5 years, except for treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, or in situ breast ductal carcinoma.~* Participant has a known history of active tuberculosis.~* Participant has a history of suicidal behaviour (i.e. 'actual suicide attempt', 'interrupted attempt', 'aborted attempt', or 'preparatory acts or behaviour') based on the Columbia-Suicide Severity Rating Scale (C-SSRS) questionnaire at screening or baseline.~* Participant has any suicidal ideation of severity 4 or 5 ('some intent to act, no plan' or 'specific plan and intent') based on the C-SSRS questionnaire at screening or baseline.~* Participant has a Patient Health Questionnaire-8 (PHQ-8) score of ≥10, corresponding to moderate to severe depression at screening or baseline.~* Participant has previously been treated with any anti-interleukin (IL)-17A, anti-IL 17 receptor subunit A, or anti-IL-23 besides ustekinumab.~* Participant has known or suspected hypersensitivity to any component(s) of the IMPs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (brodalumab + dummy 1) (Type: EXPERIMENTAL): Participants receive:~* Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~* Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks.
- Arm 2 (guselkumab + dummy 2) (Type: ACTIVE_COMPARATOR): Participants receive:~* Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~* Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).